An assay that measures C1 inhibitor (C1-INH) activity on a dried blood spot after a blood sample is blotted onto a piece of filter paper appears to work as well as a standard, color-based assay to diagnose hereditary angioedema (HAE) and is easier to handle, a study found. Dried…
Pharvaris plans a trial of deucrictibant to treat acquired angioedema this year, following promising data showing the experimental oral small molecule helped to stop or prevent swelling attacks in three patients. The company has been testing deucrictibant in a pair of Phase 3 trials, CHAPTER-3 (NCT06669754)…
Garadacimab appears to be safe for long-term use as prophylaxis, or preventive treatment, reducing the frequency of swelling attacks in adults and adolescents with hereditary angioedema (HAE), according to an interim analysis of data from an ongoing Phase 3 extension study sponsored by its developer, CSL…
Many people with hereditary angioedema (HAE) delay on-demand treatment for their attacks because they think the swelling isn’t severe enough or due to high costs and challenges related to injection, which can worsen symptoms, a survey study finds. “Survey results highlight that decision making regarding on-demand treatment in HAE…
People with hereditary angioedema (HAE) who have normal C1-inhibitor (C1-INH) levels and activity appear to have more active disease and more severe symptoms than those with HAE type 1 or 2, a real-world study found. These patients also “experience greater impairment to their quality of life, work, and daily functioning,”…
Transitioning from other prophylactic, or preventive, treatments, to Orladeyo (berotralstat) or Takhzyro (lanadelumab) can take some time and adjustment, but helps to safely prevent swelling episodes in hereditary angioedema (HAE) patients. That’s according to a study reporting the process of such a treatment transition for four family members…
Switching to Orladeyo (berotralstat) may help reduce the frequency and duration of swelling attacks in people with hereditary angioedema (HAE) who have normal levels and activity of a protein called C1-inhibitor, according to a European case series. These data add “clinically relevant evidence” to a growing body of…
An immediate-release capsule of deucrictibant that’s being developed by Pharvaris continues to show promise as an on-demand and preventive treatment for attacks of hereditary angioedema (HAE). “We believe deucrictibant is the only oral molecule with the potential to address both the on-demand and prophylactic treatment modalities for people…
A young woman who developed angioedema of the small bowel after taking two different angiotensin-converting enzyme (ACE) inhibitors showed elevated D-dimer blood levels, according to a pair of researchers in China. Stopping the medication quickly eased her angioedema symptoms. Her D-dimer levels dropped to normal, too, leading researchers…
A man in Japan may have developed acquired angioedema as a late complication of graft-versus-host disease, which occurred when stem cells from a cord blood transplant he received to treat cancer turned against his own body, according to a recent report. A diagnosis was made based on a…
Get regular updates to your inbox.
